Summit Therapeutics Inc. has announced the initiation of its global Phase III clinical trial, known as HARMONi-10, which will evaluate ivonescimab against durvalumab as a consolidation therapy for patients with unresectable Stage III non-small cell lung cancer (NSCLC). This trial is significant as it represents a major step in the company's ongoing efforts to expand its oncology portfolio.
The HARMONi-10 trial is designed to assess the efficacy of ivonescimab, a novel PD-1 x VEGF bispecific antibody, in patients who have not experienced disease progression following platinum-based concurrent chemoradiation therapy. The trial aims to deepen or prolong the response to initial treatment and delay or prevent the return of cancer.
Summit Therapeutics, headquartered in Miami, Florida, is a biopharmaceutical company focused on developing therapies for serious unmet medical needs. The company operates under the Standard Industrial Classification (SIC) code 2834, which pertains to pharmaceutical preparations. Its shares are traded on the Nasdaq under the ticker symbol SMMT.
According to the recent SEC filing (accession number 0001599298-26-000094), the global clinical trial site activations for HARMONi-10 are expected to begin in the fourth quarter of 2026. This trial is the sixth sponsored Phase III study of ivonescimab and the fourth focusing on NSCLC, following previous trials HARMONi, HARMONi-3, and HARMONi-7.
In the filing, Summit highlighted the urgency of this trial, with Dr. Maky Zanganeh, President and Co-CEO, stating, “In this curative-intent setting, this is a gap we are determined to close.” The company believes that ivonescimab has the potential to outperform durvalumab, the current standard of care, in preventing disease progression.
The initiation of HARMONi-10 may have implications for various stakeholders, including patients with advanced lung cancer, healthcare providers, and investors interested in the pharmaceutical sector. The trial's success could lead to a new treatment option for patients suffering from this challenging condition.
Looking ahead, Summit Therapeutics is expected to provide updates on the progress of the HARMONi-10 trial as site activations commence. The filing does not specify any further actions or upcoming filings related to this trial.
Read Next
Sven-Olof Lindblad sells shares in Lindblad Expeditions
Zeo Energy CEO Timothy Bridgewater Acquires 107,955 Shares
Manthripragada Vijay Acquires Additional Shares in Onterris
Laws James Acquires Shares in Onterris, Inc. via RSUs
Eightco Holdings CEO Acquires 100,000 Shares of Stock
Eightco CFO Vroman Acquires 15,000 Shares in Stock Transaction





